Jiangsu Recbio Technology Past Earnings Performance
Past criteria checks 0/6
Jiangsu Recbio Technology's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 72.7% per year.
Key information
-21.7%
Earnings growth rate
-14.4%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 72.7% |
| Return on equity | -53.5% |
| Net Margin | -1,882.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Jiangsu Recbio Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 30 | -572 | 152 | 488 |
| 30 Sep 23 | 19 | -609 | 160 | 549 |
| 30 Jun 23 | 8 | -646 | 167 | 610 |
| 31 Mar 23 | 7 | -684 | 165 | 663 |
| 31 Dec 22 | 5 | -723 | 164 | 716 |
| 30 Sep 22 | 6 | -673 | 151 | 637 |
| 30 Jun 22 | 8 | -677 | 143 | 623 |
| 31 Mar 22 | 7 | -667 | 145 | 548 |
| 31 Dec 21 | 6 | -658 | 147 | 473 |
| 30 Sep 21 | 3 | -627 | 126 | 450 |
| 31 Dec 20 | 1 | -179 | 18 | 131 |
Quality Earnings: 2179 is currently unprofitable.
Growing Profit Margin: 2179 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2179 is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.
Accelerating Growth: Unable to compare 2179's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2179 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2179 has a negative Return on Equity (-53.45%), as it is currently unprofitable.